| DC Field | Value | Language |
|---|
| dc.contributor.author | Berezhnova, T. A. | - |
| dc.contributor.author | Dyadina, K. S. | - |
| dc.contributor.author | Kulintsova, Ya. V. | - |
| dc.date.accessioned | 2022-05-05T07:48:56Z | - |
| dc.date.available | 2022-05-05T07:48:56Z | - |
| dc.date.issued | 2020 | - |
| dc.identifier.citation | Berezhnova, T.A. Immune-metabolic therapy of purulent inflammatory diseases / T.A. Berezhnova, K.S. Dyadina, Kulintsova Ya.V. // Research Results in Pharmacology. - 2020. - Vol.6, №4.-P. 1-6. - Doi: 10.3897/rrpharmacology.6.55628. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46605 | - |
| dc.description.abstract | It was found that the standard therapy to treat exacerbated chronic salpingo-oophoritis reduced inflammatory manifestations after 10-14 days; however, the risk of complications and relapse of the disease remained. Immunomax provided satisfactory second-order normalization of the immunological and metabolic parameters, ultimate normalization of pro-inflammatory parameters and absolutely no positive effect on the clinical parameters in patients with chronic salpingo-oophoritis in the acute stage, when compared with the standard treatment | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | immunomax | ru |
| dc.subject | hypoxene | ru |
| dc.subject | salpingo-oophoritis | ru |
| dc.subject | bacterial vaginosis | ru |
| dc.subject | purulent inflammatory diseases | ru |
| dc.title | Immune-metabolic therapy of purulent inflammatory diseases | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 6, № 4
|
